131 related articles for article (PubMed ID: 36707321)
1. Re: Jonas Hugosson, Marianne Månsson, Jona Wallström, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med 2022;387:2126-37.
Lenfant L; Mozer P; Seisen T
Eur Urol Oncol; 2023 Apr; 6(2):235. PubMed ID: 36707321
[No Abstract] [Full Text] [Related]
2. Re: Jonas Hugosson, Marianne Månsson, Jona Wallström, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med 2022;387:2126-37.
Morote J
Eur Urol Oncol; 2023 Apr; 6(2):234. PubMed ID: 36894492
[No Abstract] [Full Text] [Related]
3. After PSA screening, MRI-targeted vs. systematic biopsy detected fewer clinically insignificant prostate cancers.
Hoffman RM
Ann Intern Med; 2023 Apr; 176(4):JC44. PubMed ID: 37011398
[TBL] [Abstract][Full Text] [Related]
4. Re: Jonas Hugosson, Monique J. Roobol, Marianne Månsson, et al. A 16-yr Follow-up of the European Randomized Study of Screening for Prostate Cancer. Eur Urol 2019;76:43-51: Mortality in the Age Group ≥70 yr and the Case of Italy.
Donzelli A; Castelluzzo G; Giudicatti G
Eur Urol; 2020 Mar; 77(3):e70-e71. PubMed ID: 31443958
[No Abstract] [Full Text] [Related]
5. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
6. Targeted Prostate Biopsy and MR-Guided Therapy for Prostate Cancer.
Woodrum DA; Kawashima A; Gorny KR; Mynderse LA
Adv Exp Med Biol; 2018; 1096():159-184. PubMed ID: 30324353
[TBL] [Abstract][Full Text] [Related]
7. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
[TBL] [Abstract][Full Text] [Related]
8. Re: Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
Bratt O; Auvinen A
Eur Urol; 2023 Apr; 83(4):370-371. PubMed ID: 36623950
[No Abstract] [Full Text] [Related]
9. Re: Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
Kenigsberg AP; Ahdoot M; Turkbey B; Pinto PA
Eur Urol; 2023 Jun; 83(6):582-583. PubMed ID: 36907691
[No Abstract] [Full Text] [Related]
10. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
[TBL] [Abstract][Full Text] [Related]
11. Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial.
Nam R; Patel C; Milot L; Hird A; Wallis C; Macinnis P; Singh M; Emmenegger U; Sherman C; Haider MA
BMJ Open; 2022 Nov; 12(11):e059482. PubMed ID: 36351725
[TBL] [Abstract][Full Text] [Related]
12. Impact of prostate-specific antigen screening on tumor size in patients with prostate cancer in a super-aging district in Kyoto, Japan.
Matsugasumi T; Okihara K; Tsujimoto M; Sato O; Imura T; Yamada Y; Fujihara A; Shiraishi T; Hongo F; Ukimura O
Int J Clin Oncol; 2021 Dec; 26(12):2303-2309. PubMed ID: 34537890
[TBL] [Abstract][Full Text] [Related]
13. The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study.
Getaneh AM; Heijnsdijk EAM; de Koning HJ
Sci Rep; 2021 Jan; 11(1):1801. PubMed ID: 33469144
[TBL] [Abstract][Full Text] [Related]
14. Seminar: Revisiting the value of PSA-based prostate cancer screening Essay No 5: Should men undergo MRI before prostate biopsy? (Pro).
Maffei D; Giganti F; Moore CM
Urol Oncol; 2023 Feb; 41(2):88-91. PubMed ID: 35871993
[TBL] [Abstract][Full Text] [Related]
15. Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial.
Wallström J; Geterud K; Kohestani K; Maier SE; Pihl CG; Socratous A; Stranne J; Arnsrud-Godtman R; Månsson M; Hellström M; Hugosson J
Eur Urol Oncol; 2022 Feb; 5(1):54-60. PubMed ID: 34580053
[TBL] [Abstract][Full Text] [Related]
16. Re: Prostate Cancer Screening Using a Combination of Risk-prediction, MRI, and Targeted Prostate Biopsies (STHLM3-MRI): A Prospective, Population-based, Randomised, Open-label, Non-inferiority Trial.
Raslan M; Mercader C; Lamb AD
Eur Urol; 2022 May; 81(5):543-544. PubMed ID: 35105477
[No Abstract] [Full Text] [Related]
17. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
18. Failure to detect prostate cancer in the PSA era: comments on N Engl J Med 2003; 349: 215-224 and N Engl J Med 2003; 349: 335-342.
Platz EA; De Marzo AM; Giovannucci E
Cancer Causes Control; 2004 Feb; 15(1):91-4. PubMed ID: 14970739
[No Abstract] [Full Text] [Related]
19. Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study.
Rannikko A; Leht M; Mirtti T; Kenttämies A; Tolonen T; Rinta-Kiikka I; Kilpeläinen TP; Natunen K; Lilja H; Lehtimäki T; Raitanen J; Kujala P; Ronkainen J; Matikainen M; Petas A; Taari K; Tammela T; Auvinen A
BJU Int; 2022 Aug; 130(2):193-199. PubMed ID: 34958531
[TBL] [Abstract][Full Text] [Related]
20. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
